Benign Prostatic Hyperplasia and Ischemic Heart DIsease

• Status: Completed
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: Male

Summary

To examine the dynamics of 24 - hours ECG monitoring parameters (Holter monitoring) in patients with ischaemic heart disease (IHD) before and after treatment of voiding dysfunctions resulted from benign prostatic hyperplasia (BPH) with the indications for either conservative or operative treatment.

A total of eighty-three 57-to-81-year-old (mean age 70.4±5.75 years) patients with BPH and accompanying IHD were examined at the Institute of Urology and Human Reproductive Health and Clinic of Cardiology of the Sechenov University.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: I.M. Sechenov First Moscow State Medical University
• Treatments: Tamsulosin

Criteria

Inclusion Criteria:

• LUTS/BPH, with the total score by the IPSS more than or equal to 8;

• Functional class II-IV angina of effort;

• Non-ST segment depression postinfarction cardiosclerosis.

Exclusion Criteria:

• Presence of cystostomic drainage;

• Long-term LUTS/BPH therapy of prostatic hyperplasia (alpha-adrenoblockers, 5-alpha-reductase inhibitors and others) - for the groups of patients of conservative treatment of BPH;

• Patients after operative treatment of prostatic hyperplasia (TUR of prostatic hyperplasia, transvesical adenomectomy, etc.);

• Urinary bladder stones;

• Acute urinary retention;

• Changes on the ECG hampering its interpretation (complete left bundle branch block, cicatricial changes after endured myocardial infarction, permanent form of ciliary arrhythmia);

• Acute forms of ischaemic heart disease.